A novel highly reactive Fab antibody for breast cancer tissue diagnostics and staging also discriminates a subset of good prognostic triple-negative breast cancers

Cancer Letters

Volumn 343, Issue 2, 2014, Pages 275-285

  Araújo, Thaise G ^a   Paiva, Carlos E ^b   Rocha, Rafael M ^c   Maia, Yara C P ^a   Sena, Angela A S ^a   Ueira Vieira, Carlos ^a   Carneiro, Ana Paula ^a   Almeida, Juliana F ^a   de Faria, Paulo R ^a   Santos, Donizeti W ^a   Calábria, Luanda ^a   Alcântara, Tânia M ^a   Soares, Fernando A ^c   Goulart, Luiz R ^a,d  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b BARRETOS CANCER HOSPITAL   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Combinatorial library; Phage display; Recombinant antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 10; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; PROGESTERONE RECEPTOR; PROTEIN FABC4; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ANTIBODY LIBRARY; ANTIBODY SPECIFICITY; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY;

BREAST CANCER; COMBINATORIAL LIBRARY; PHAGE DISPLAY; RECOMBINANT ANTIBODY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE LIBRARY; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84891830814     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.029     Document Type: Article

References (42)

1. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics. CA Cancer J. Clin. 2011, 61(2011):409-418.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
3. Geyer F.C., Marchio C., Reis-Filho J.S. The role of molecular analysis in breast cancer. Pathology 2009, 41:77-88.
4. Latterich M., Abramovitz M., Leyland-Jones B. Proteomics: new technologies and clinical applications. Eur. J. Cancer 2008, 44:2737-2741.
5. Hanby A.M. The pathology of breast cancer and the role of the histopathology laboratory. Clin. Oncol. (R Coll Radiol) 2005, 17:234-239.
6. Popkov M., Rader C., Barbas C.F. Isolation of human prostate cancer cell reactive antibodies using phage display technology. J. Immunol. Methods 2004, 291:137-151.
7. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
8. Kim S.J., Park Y., Hong H.J. Antibody engineering for the development of therapeutic antibodies. Mol. Cells 2005, 20:17-29.
9. Ben-Kasus T., Schechter B., Sela M., Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol. Oncol. 2007, 1:42-54.
10. Hall P.S., Cameron D.A. Current perspective - trastuzumab. Eur. J. Cancer 2009, 45:12-18.
11. Hust M., Dubel S. Mating antibody phage display with proteomics. Trends Biotechnol. 2004, 22:8-14.
12. Pansri P., Jaruseranee N., Rangnoi K., Kristensen P., Yamabhai M. A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol. 2009, 9:6.
13. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., Kontermann R.E., Jones P.T., Low N.M., Allison T.J., et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994, 13:3245-3260.
14. Azzazy H.M., Highsmith W.E. Phage display technology: clinical applications and recent innovations. Clin. Biochem. 2002, 35:425-445.
15. Smith G.P., Petrenko V.A. Phage display. Chem. Rev. 1997, 97:391-410.
16. de Haard H.J., van Neer N., Reurs A., Hufton S.E., Roovers R.C., Henderikx P., de Bruine A.P., Arends J.W., Hoogenboom H.R. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 1999, 274:18218-18230.
17. Wu B.P., Xiao B., Wan T.M., Zhang Y.L., Zhang Z.S., Zhou D.Y., Lai Z.S., Gao C.F. Construction and selection of the natural immune Fab antibody phage display library from patients with colorectal cancer. World J. Gastroenterol. 2001, 7:811-815.
18. Cai X., Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc. Natl. Acad. Sci. USA 1995, 92:6537-6541.
19. Somers V.A., Brandwijk R.J., Joosten B., Moerkerk P.T., Arends J.W., Menheere P., Pieterse W.O., Claessen A., Scheper R.J., Hoogenboom H.R., Hufton S.E. A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J. Immunol. 2002, 169:2772-2780.
20. Mintz P.J., Kim J., Do K.A., Wang X., Zinner R.G., Cristofanilli M., Arap M.A., Hong W.K., Troncoso P., Logothetis C.J., Pasqualini R., Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat. Biotechnol. 2003, 21:57-63.
21. Zhang Q., Zhang S.H., Su M.Q., Bao G.Q., Liu J.Y., Yi J., Shen J.J., Hao X.K. Guided selection of an anti-gamma-seminoprotein human Fab for antibody directed enzyme prodrug therapy of prostate cancer. Cancer Immunol. Immunother. 2007, 56:477-489.
22. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 1991, 222:581-597.
23. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
24. Andris-Widhopf J., Steinberger P., Fuller R., Rader C., Barbas C. Generation of antibody libraries: PCR amplification and assembly of light-and heavy-chain coding sequences. Phage Display Laboratory Manual 2001, 9.1-9.22. Cold Spring Harbor Laboratory Press, New York.
25. Ewing B., Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 1998, 8:186-194.
26. Nagai M.A., Fregnani J.H., Netto M.M., Brentani M.M., Soares F.A. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res. Treat. 2007, 106:49-56.
27. Chung L., Shibli S., Moore K., Elder E.E., Boyle F.M., Marsh D.J., Baxter R.C. Tissue biomarkers of breast cancer and their association with conventional pathologic features. Br. J. Cancer 2013, 108:351-360.
28. Paramio J.M., Jorcano J.L. Beyond structure: do intermediate filaments modulate cell signalling?. BioEssays: News Rev. Mol., Cell. Dev. Biol. 2002, 24:836-844.
29. Omary M.B., Ku N.O., Tao G.Z., Toivola D.M., Liao J. "Heads and tails" of intermediate filament phosphorylation: multiple sites and functional insights. Trends Biochem. Sci. 2006, 31:383-394.
30. Zong J., Guo C., Liu S., Sun M.Z., Tang J. Proteomic research progress in lymphatic metastases of cancers. Clin. Transl. Oncol. 2012, 14:21-30.
31. Yang X.R., Xu Y., Shi G.M., Fan J., Zhou J., Ji Y., Sun H.C., Qiu S.J., Yu B., Gao Q., He Y.Z., Qin W.Z., Chen R.X., Yang G.H., Wu B., Lu Q., Wu Z.Q., Tang Z.Y. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin. Cancer Res. 2008, 14:3850-3859.
32. Carrilho C., Alberto M., Buane L., David L. Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcinomas. Human Pathol. 2004, 35:546-551.
33. Relchelt J., Magin T.M. Hyperproliferation, induction of c-Myc and 14-3-3 sigma, but no cell fragility in keratin-10-null mice. J. Cell Sci. 2002, 115:2639-2650.
34. Magin T.M., Vijayaraj P., Leube R.E. Structural and regulatory functions of keratins. Exp. Cell Res. 2007, 313:2021-2032.
35. Schier R., Bye J., Apell G., McCall A., Adams G.P., Malmqvist M., Weiner L.M., Marks J.D. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 1996, 255:28-43.
36. Begent R.H., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P., Hope-Stone L.D., Cushen N., Keep P.A., Johnson C.J., Hawkins R.E., Hilson A.J., Robson L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 1996, 2:979-984.
37. Osbourn J.K., Field A., Wilton J., Derbyshire E., Earnshaw J.C., Jones P.T., Allen D., McCafferty J. Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology 1996, 2:181-196.
38. Bhargava R., Beriwal S., Dabbs D.J. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am. J. Clin. Pathol. 2007, 127:103-113.
39. Litzenburger B.C., Creighton C.J., Tsimelzon A., Chan B.T., Hilsenbeck S.G., Wang T., Carboni J.M., Gottardis M.M., Huang F., Chang J.C., Lewis M.T., Rimawi M.F., Lee A.V. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin. Cancer Res. 2011, 17:2314-2327.
40. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 2011, 22:1736-1747.
41. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728.
42. Metzger-Filho O., Tutt A., de Azambuja E., Saini K.S., Viale G., Loi S., Bradbury I., Bliss J.M., Azim H.A., Ellis P., Di Leo A., Baselga J., Sotiriou C., Piccart-Gebhart M. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 2012, 30:1879-1887.